ONGOING RESEARCH
In terms of research, molecular biologists 2 are studying genetic markers that can determine those premalignant lesions that will progress to cancer. These markers could also detect recurrence after treatment. Stem cell researchers 3 are studying those cancer cells that exhibit immortality rather than the larger population of cancer cells that will never divide and simply die naturally. Clearly these stem cells are the targets that clinicians should aim to destroy but unfortunately they seem resistant to current radiotherapy and chemotherapy regimes. These cells also seem to be the ones that can metastasise. Other cells that are coming under scrutiny are tumour fibroblasts and blood vessel progenitor cells.
Oncologists are now assessing better agents to target the cancer cells or their blood supply specifically. These agents are usually antibodies to growth factor receptors on the cancer cell itself. They have the advantage of causing minimal harm to the majority of normal cells as they only target cells that carry the receptor. Other researchers are exploring the possibility of mouth cancers of viral origin. Much interest has been generated by the role of HPV 16 in oropharyngeal cancer and the possibility that vaccination against this virus will reduce the incidence of this cancer in young people. But as the 1994 BMJ editorial stated the best way we can improve the prognosis for all mouth cancer patients is to get them from the street to the PCP rapidly and then to the correct surgeon by immediate referral. While we can applaud the improvement in patient and PCP knowledge from successive campaigns there remains a significant cohort of patients still presenting with advanced disease and poorer cure rates despite more costly and invasive treatment. Studies of telephone enquiries to GMPs' and GDPs' receptionists demonstrate that these 'gatekeepers' should also be included in further mouth cancer education. Male patients from low socio-economic groups still have not absorbed the message that their mouth ulcer might be cancerous.
There is one innovation that will already aid this rapid transit from PCP to surgeon. The Saving Faces Charity has piloted an electronic diagnostic service for PCPs. This gives valuable advice on each referral and recommends to whom the patient should be referred and the urgency with direct email and fax numbers for the surgeon. The response time is within three working days; 70 patients have been referred, two of whom had cancer. They were seen at their local hospitals by the treating surgeon within two days of referral with excellent outcomes. However, we still have to find better methods to inform the low socio-economic male patient as a target group.
